Designing a First-in-Human Dose-Escalation Study of an Oral RAS(ON) Multi-Selective Inhibitor in Advanced RAS-Mutant Solid Tumors: Scientific and Regulatory Justification and Phase 1 Protocol Synopsis
The first human dose of an oncology drug must be chosen with less information than any later dose, and the design that surrounds it has to protect patients who cannot be offered the safety margin a healthy volunteer would receive. This article develops the scientific and regulatory justification for a hypothetical first-in-human study of an oral RAS(ON) multi-selective inhibitor, a small molecule that forms a tri-complex with an intracellular chaperone and active, GTP-bound RAS, in adults with advanced RAS-mutant solid tumors. It derives a 10 mg starting dose from assumed ICH S9 toxicology benchmarks, specifies eight dose levels from 10 to 400 mg once daily under a traditional 3+3 design with a single-dose pharmacokinetic run-in, and presents a complete protocol synopsis: objectives, eligibility, dose-limiting toxicity rules, a schedule of events, safety monitoring, and statistics for up to 48 participants. The article also corrects a design inconsistency common in student protocols, in which single- and multiple-ascending-dose labels are applied to an oncology study that has neither, and closes with recommendations for first-in-human oncology design.Keywords: first-in-human; RAS(ON) inhibitor; ICH S9; dose escalation; 3+3 design; starting dose; Phase 1 protocol; IND
Authors
- Avinash Dundigalla
- Peivand Pirouzi
- Daxaben Jigneshkumar Patel
- Afeefa Mahmood
- Kritica
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426098
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00